ES2622460T3
(es)
|
2007-09-26 |
2017-07-06 |
Ucb Biopharma Sprl |
Fusiones de anticuerpos con doble especificidad
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
WO2010035012A1
(en)
|
2008-09-26 |
2010-04-01 |
Ucb Pharma S.A. |
Biological products
|
ES2657220T3
(es)
|
2008-10-02 |
2018-03-02 |
Aptevo Research And Development Llc |
Proteínas de unión multi-diana antagonistas de CD86
|
MX2011010159A
(es)
|
2009-04-02 |
2011-10-17 |
Roche Glycart Ag |
Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla.
|
JP5616428B2
(ja)
|
2009-04-07 |
2014-10-29 |
ロシュ グリクアート アクチェンゲゼルシャフト |
三価の二重特異性抗体
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
US8703132B2
(en)
|
2009-06-18 |
2014-04-22 |
Hoffmann-La Roche, Inc. |
Bispecific, tetravalent antigen binding proteins
|
JO3182B1
(ar)
*
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
WO2011034605A2
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
ME02505B
(me)
*
|
2009-12-29 |
2017-02-20 |
Aptevo Res & Development Llc |
Heterodimerni vezujući proteini i njihove upotrebe
|
GB201000467D0
(en)
*
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
EP2824457A1
(en)
|
2010-07-19 |
2015-01-14 |
F. Hoffmann-La Roche AG |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
MX2013000667A
(es)
|
2010-07-19 |
2013-02-27 |
Hoffmann La Roche |
Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anticancer.
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
CA2805564A1
(en)
|
2010-08-05 |
2012-02-09 |
Stefan Jenewein |
Anti-mhc antibody anti-viral cytokine fusion protein
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
RS59589B1
(sr)
|
2010-11-05 |
2019-12-31 |
Zymeworks Inc |
Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
|
CN103429737B
(zh)
|
2010-11-30 |
2020-07-14 |
中外制药株式会社 |
细胞毒诱导治疗剂
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
TW201309330A
(zh)
*
|
2011-01-28 |
2013-03-01 |
Abbott Lab |
包含糖基化抗體之組合物及其用途
|
WO2012116926A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Antigen binding proteins
|
AR085403A1
(es)
|
2011-02-28 |
2013-09-25 |
Hoffmann La Roche |
Proteinas monovalentes que se unen a antigenos
|
EP2699602B1
(en)
*
|
2011-04-19 |
2017-03-01 |
Merrimack Pharmaceuticals, Inc. |
Bispecific anti-igf-1r and anti-erbb3 antibodies
|
WO2012143379A1
(en)
|
2011-04-20 |
2012-10-26 |
Roche Glycart Ag |
Method and constructs for the ph dependent passage of the blood-brain-barrier
|
BR112013032235A2
(pt)
|
2011-06-15 |
2016-11-22 |
Hoffmann La Roche |
anticorpos do receptor de epo anti-humano e métodos de uso
|
AR086982A1
(es)
|
2011-06-22 |
2014-02-05 |
Hoffmann La Roche |
Eliminacion de celulas diana por parte de celulas t citotoxicas especificas de virus utilizando complejos que comprenden mhc de clase i
|
PL2748202T3
(pl)
*
|
2011-08-23 |
2018-12-31 |
Roche Glycart Ag |
Dwuswoiste cząsteczki wiążące antygen
|
CN107586340B
(zh)
|
2011-08-23 |
2022-01-21 |
罗切格利卡特公司 |
对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法
|
BR112014004166A2
(pt)
*
|
2011-08-23 |
2018-05-29 |
Roche Glycart Ag |
anticorpo biespecífico compreendendo pelo menos dois fragmentos fab, célula hospedeira procariótica ou eucariótica, metodo de produção de um anticorpo, imunoconjugado e invenção
|
US20130078250A1
(en)
*
|
2011-08-23 |
2013-03-28 |
Oliver Ast |
Bispecific t cell activating antigen binding molecules
|
CA2837975C
(en)
*
|
2011-08-23 |
2022-04-05 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
EP2760892A1
(en)
|
2011-09-29 |
2014-08-06 |
Apo-T B.V. |
Multi-specific binding molecules targeting aberrant cells
|
CN104080811B
(zh)
|
2011-11-04 |
2019-09-27 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
BR112014011535A2
(pt)
|
2011-12-19 |
2017-05-09 |
Hoffmann La Roche |
método para a determinação in vitro e imunológica de presença da presença e/ou da quantidade de um parceiro de ligação, método in vitro e utilização de um anticorpo
|
CN104011080B
(zh)
|
2011-12-22 |
2017-10-20 |
弗·哈夫曼-拉罗切有限公司 |
用于真核细胞的全长抗体展示***及其用途
|
CA3149402A1
(en)
|
2011-12-22 |
2013-06-27 |
F. Hoffman-La Roche Ag |
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
|
KR102080356B1
(ko)
|
2011-12-22 |
2020-02-24 |
에프. 호프만-라 로슈 아게 |
발현 벡터 구성, 신규한 생산 세포 생성 방법 및 폴리펩티드의 재조합 생산을 위한 그의 용도
|
US10946104B2
(en)
|
2012-01-13 |
2021-03-16 |
Apo-Tb.V. |
Aberrant cell-restricted immunoglobulins provided with a toxic moiety
|
CN104105966B
(zh)
|
2012-02-01 |
2016-10-26 |
弗·哈夫曼-拉罗切有限公司 |
用于检测多特异性结合物的结合搭档的方法
|
JP6363021B2
(ja)
|
2012-02-03 |
2018-07-25 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗原をトランスフェクトされたt細胞を伴う二重特異性抗体分子及び医薬におけるそれらの使用
|
RU2644341C2
(ru)
|
2012-02-10 |
2018-02-08 |
Дженентек, Инк. |
Одноцепочечные антитела и другие гетеромультимеры
|
MX360352B
(es)
|
2012-02-15 |
2018-10-30 |
Hoffmann La Roche |
Cromatografia de afinidad basada en receptores fc.
|
WO2013134414A1
(en)
*
|
2012-03-06 |
2013-09-12 |
Galaxy Biotech, Llc |
Bispecific antibodies with an fgf2 binding domain
|
CA2870545A1
(en)
|
2012-04-20 |
2013-10-24 |
Emergent Product Development Seattle, Llc |
Cd3 binding polypeptides
|
CN104379604A
(zh)
*
|
2012-05-24 |
2015-02-25 |
弗·哈夫曼-拉罗切有限公司 |
多特异性抗体
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
CA2871882A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
EP2867253B1
(en)
|
2012-06-27 |
2016-09-14 |
F. Hoffmann-La Roche AG |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
EP3339328A1
(en)
|
2012-07-04 |
2018-06-27 |
F. Hoffmann-La Roche AG |
Anti-biotin antibodies and methods of use
|
HUE029435T2
(en)
|
2012-07-04 |
2017-02-28 |
Hoffmann La Roche |
Anti-theophylline antibodies and methods of their application
|
CN107973856B
(zh)
|
2012-07-04 |
2021-11-23 |
弗·哈夫曼-拉罗切有限公司 |
共价连接的抗原-抗体缀合物
|
ES2627482T3
(es)
|
2012-07-13 |
2017-07-28 |
F. Hoffmann-La Roche Ag |
Procedimiento para la detección de una proteína de unión multiespecífica
|
US20140072581A1
(en)
*
|
2012-07-23 |
2014-03-13 |
Zymeworks Inc. |
Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains
|
RU2646159C2
(ru)
|
2012-09-14 |
2018-03-01 |
Ф. Хоффманн-Ля Рош Аг |
Способ получения и отбора молекул, включающих по меньшей мере две различные группировки, и их применение
|
EP2905290B1
(en)
|
2012-10-05 |
2019-12-04 |
Kyowa Kirin Co., Ltd. |
Heterodimeric protein composition
|
KR20150064068A
(ko)
*
|
2012-10-08 |
2015-06-10 |
로슈 글리카트 아게 |
2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법
|
EP2917243B1
(en)
|
2012-11-08 |
2018-03-14 |
F.Hoffmann-La Roche Ag |
Her3 antigen binding proteins binding to the beta-hairpin of her3
|
ES2649991T3
(es)
*
|
2012-11-19 |
2018-01-16 |
Baliopharm Ag |
Anticuerpo biespecífico recombinante que se une a CD20 y CD95
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
CA2893562C
(en)
|
2012-11-28 |
2023-09-12 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
GB201223276D0
(en)
*
|
2012-12-21 |
2013-02-06 |
Ucb Pharma Sa |
Antibodies and methods of producing same
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
WO2014110601A1
(en)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Novel heterodimeric proteins
|
MY192312A
(en)
*
|
2013-02-26 |
2022-08-17 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
MX2015010843A
(es)
*
|
2013-02-26 |
2016-04-04 |
Roche Glycart Ag |
Moleculas biespecificas de union al antigeno que activan celulas t.
|
CN105143270B
(zh)
|
2013-02-26 |
2019-11-12 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
WO2014144357A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Merck Patent Gmbh |
Tetravalent bispecific antibodies
|
DK2970486T3
(en)
|
2013-03-15 |
2018-08-06 |
Xencor Inc |
MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
KR102049990B1
(ko)
*
|
2013-03-28 |
2019-12-03 |
삼성전자주식회사 |
c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
KR20210094669A
(ko)
|
2013-04-29 |
2021-07-29 |
에프. 호프만-라 로슈 아게 |
인간 fcrn-결합 변형된 항체 및 사용 방법
|
CA2904805A1
(en)
|
2013-04-29 |
2014-11-06 |
F. Hoffmann-La Roche Ag |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
EP3327034A1
(en)
|
2013-04-29 |
2018-05-30 |
F. Hoffmann-La Roche AG |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
WO2015025054A1
(en)
|
2013-08-22 |
2015-02-26 |
Medizinische Universität Wien |
Dye-specific antibodies for prestained molecular weight markers and methods producing the same
|
CA2922912A1
(en)
|
2013-10-11 |
2015-04-16 |
F. Hoffmann-La Roche Ag |
Multispecific domain exchanged common variable light chain antibodies
|
CN104558194B
(zh)
*
|
2013-10-17 |
2018-04-27 |
泰州迈博太科药业有限公司 |
一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
|
EP3783020A1
(en)
|
2013-11-21 |
2021-02-24 |
F. Hoffmann-La Roche AG |
Anti-alpha-synuclein antibodies and methods of use
|
CA2932958A1
(en)
|
2013-12-20 |
2015-06-25 |
F. Hoffmann-La Roche Ag |
Humanized anti-tau(ps422) antibodies and methods of use
|
RU2016129517A
(ru)
|
2013-12-20 |
2018-01-25 |
Ф. Хоффманн-Ля Рош Аг |
Биспецифические антитела к her2 и способы применения
|
TW201609805A
(zh)
*
|
2013-12-23 |
2016-03-16 |
美國禮來大藥廠 |
結合egfr及met之多功能抗體
|
MX2016008189A
(es)
|
2014-01-03 |
2016-09-29 |
Hoffmann La Roche |
Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
|
PL3089996T3
(pl)
|
2014-01-03 |
2021-12-13 |
F. Hoffmann-La Roche Ag |
Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg
|
CA2930046A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Covalently linked polypeptide toxin-antibody conjugates
|
KR102381685B1
(ko)
|
2014-01-06 |
2022-04-01 |
에프. 호프만-라 로슈 아게 |
1가 혈액 뇌 장벽 셔틀 모듈
|
CN110903398B
(zh)
|
2014-01-15 |
2023-08-15 |
豪夫迈·罗氏有限公司 |
具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
|
ME03666B
(me)
|
2014-03-28 |
2020-10-20 |
Xencor Inc |
Bispecifična antitela koja se vezuju za cd38 i cd3
|
EP3126389A1
(en)
|
2014-04-02 |
2017-02-08 |
F. Hoffmann-La Roche AG |
Method for detecting multispecific antibody light chain mispairing
|
IL247715B
(en)
|
2014-04-07 |
2022-07-01 |
Chugai Pharmaceutical Co Ltd |
Antigen binding molecules that activate the immune system
|
EP2930188A1
(en)
*
|
2014-04-13 |
2015-10-14 |
Affimed Therapeutics AG |
Trifunctional antigen-binding molecule
|
KR102223502B1
(ko)
*
|
2014-05-09 |
2021-03-05 |
삼성전자주식회사 |
항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
|
EP3144388B1
(en)
|
2014-05-13 |
2020-07-01 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirecting antigen-binding molecule for cells having immunosuppression function
|
EP3107938B1
(en)
|
2014-05-28 |
2022-05-04 |
Zymeworks Inc. |
Modified antigen binding polypeptide constructs and uses thereof
|
RU2718692C2
(ru)
*
|
2014-05-29 |
2020-04-13 |
Мэкроудженикс, Инк. |
Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
WO2015197736A1
(en)
|
2014-06-26 |
2015-12-30 |
F. Hoffmann-La Roche Ag |
Anti-brdu antibodies and methods of use
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
JP2017520575A
(ja)
|
2014-07-01 |
2017-07-27 |
ファイザー・インク |
二重特異的ヘテロ二量体ダイアボディおよびその使用
|
CN107074925B
(zh)
|
2014-07-10 |
2021-08-24 |
阿费里斯股份公司 |
用于预防和/或治疗亨廷顿氏病的物质和方法
|
DK3608337T3
(da)
|
2014-08-04 |
2024-06-17 |
Hoffmann La Roche |
Bispecifikke T-celleaktiverende antigenbindende molekyler
|
AR101997A1
(es)
|
2014-09-26 |
2017-01-25 |
Macrogenics Inc |
Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos
|
PL3215528T3
(pl)
|
2014-11-06 |
2020-01-31 |
F.Hoffmann-La Roche Ag |
Warianty regionu Fc ze zmodyfikowanym wiązaniem FcRn i sposoby stosowania
|
JP6576456B2
(ja)
|
2014-11-06 |
2019-09-18 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
修飾されたFcRn結合特性およびプロテインA結合特性を有するFc領域変種
|
PL3221355T3
(pl)
|
2014-11-20 |
2021-03-08 |
F. Hoffmann-La Roche Ag |
Terapia skojarzona składająca się z dwuswoistych aktywujących limfocyty T cząsteczek wiążących antygen CD3 i receptor folianowy 1 (FolR1) oraz antagonistów wiązania osi PD-1
|
KR20170084326A
(ko)
|
2014-11-26 |
2017-07-19 |
젠코어 인코포레이티드 |
Cd3 및 종양 항원과 결합하는 이종이량체 항체
|
EP3223907A2
(en)
|
2014-11-26 |
2017-10-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
EP3227341A1
(en)
|
2014-12-02 |
2017-10-11 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
|
CN107001482B
(zh)
*
|
2014-12-03 |
2021-06-15 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
ES2935274T3
(es)
*
|
2014-12-05 |
2023-03-03 |
Merck Patent Gmbh |
Anticuerpo con intercambio de dominios
|
BR112017011170A2
(pt)
|
2014-12-18 |
2018-02-27 |
Hoffmann La Roche |
método para determinar a citotoxicidade dependente do complemento de uma composição
|
US10428155B2
(en)
*
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
AU2015380455A1
(en)
|
2015-01-26 |
2017-08-03 |
Macrogenics, Inc. |
Multivalent molecules comprising DR5-binding domains
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
PL3313877T3
(pl)
|
2015-06-24 |
2020-11-02 |
F. Hoffmann-La Roche Ag |
Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania
|
JP2018519832A
(ja)
*
|
2015-06-30 |
2018-07-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
多重特異的結合タンパク質
|
GEP20227419B
(en)
|
2015-07-30 |
2022-10-10 |
Macrogenics Inc |
Pd-1-binding molecules and methods of use thereof
|
MY197562A
(en)
|
2015-09-21 |
2023-06-23 |
Aptevo Res & Development Llc |
Cd3 binding polypeptides
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
CR20180162A
(es)
|
2015-10-02 |
2018-05-25 |
Hoffmann La Roche |
Moléculas biespecíficas de unión a antígeno activadoras de células t
|
WO2017055399A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Cellular based fret assay for the determination of simultaneous binding
|
MX2018003629A
(es)
|
2015-10-02 |
2018-08-01 |
Hoffmann La Roche |
Anticuerpos anti-pd1 y metodos de uso.
|
KR20180084772A
(ko)
|
2015-10-08 |
2018-07-25 |
마크로제닉스, 인크. |
암 치료를 위한 조합 치료법
|
CN116396393A
(zh)
|
2015-10-08 |
2023-07-07 |
酵活英属哥伦比亚省公司 |
包含κ和λ轻链的抗原结合多肽构建体及其用途
|
IL295756A
(en)
|
2015-10-29 |
2022-10-01 |
Hoffmann La Roche |
Antibodies against fc-variable region and methods of use
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
US11649293B2
(en)
|
2015-11-18 |
2023-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Method for enhancing humoral immune response
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
CN108699136B
(zh)
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
CA2997406C
(en)
|
2015-12-09 |
2024-05-28 |
F. Hoffmann-La Roche Ag |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release
|
BR112018011781A2
(pt)
|
2015-12-14 |
2018-12-04 |
Macrogenics Inc |
molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
|
AU2016381964B2
(en)
|
2015-12-30 |
2024-02-15 |
Kodiak Sciences Inc. |
Antibodies and conjugates thereof
|
AU2017205089B2
(en)
|
2016-01-08 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
|
WO2017142928A1
(en)
|
2016-02-17 |
2017-08-24 |
Macrogenics, Inc. |
Ror1-binding molecules, and methods of use thereof
|
DK3433280T3
(da)
|
2016-03-22 |
2023-06-19 |
Hoffmann La Roche |
Protease-aktiverede T-celle-bispecifikke molekyler
|
EP3432927A4
(en)
*
|
2016-03-24 |
2019-11-20 |
Gensun Biopharma Inc. |
TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT
|
PE20190353A1
(es)
|
2016-04-15 |
2019-03-07 |
Macrogenics Inc |
Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos
|
EP4257613A3
(en)
|
2016-06-14 |
2023-12-13 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
MX2018015173A
(es)
|
2016-06-17 |
2019-07-04 |
Genentech Inc |
Purificacion de anticuerpos multiespecificos.
|
EP3475304B1
(en)
|
2016-06-28 |
2022-03-23 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
US20190233534A1
(en)
|
2016-07-14 |
2019-08-01 |
Fred Hutchinson Cancer Research Center |
Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
CN116731197A
(zh)
|
2016-09-19 |
2023-09-12 |
豪夫迈·罗氏有限公司 |
基于补体因子的亲和层析
|
CA3038552A1
(en)
*
|
2016-09-30 |
2018-04-05 |
Baylor College Of Medicine |
Antibody based gene therapy with tissue-directed expression
|
JP7022123B2
(ja)
|
2016-09-30 |
2022-02-17 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Cd3に対する二重特異性抗体
|
JP6785372B2
(ja)
|
2016-09-30 |
2020-11-18 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
多重特異性分子の機能分析のためのsprに基づく二重結合アッセイ
|
PE20191034A1
(es)
|
2016-10-14 |
2019-08-05 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15r y fragmentos de anticuerpo pd-1
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
CR20190297A
(es)
|
2016-11-23 |
2019-11-01 |
Bioverativ Therapeutics Inc |
Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x
|
KR102293106B1
(ko)
|
2016-12-21 |
2021-08-24 |
에프. 호프만-라 로슈 아게 |
항체의 시험관 내 당조작 방법
|
BR112019009839A2
(pt)
|
2016-12-21 |
2019-09-17 |
Hoffmann La Roche |
método para a produção enzimática de um anticorpo e anticorpo
|
KR102317884B1
(ko)
|
2016-12-21 |
2021-10-26 |
에프. 호프만-라 로슈 아게 |
항체의 시험관 내 당조작
|
US11242402B2
(en)
|
2016-12-23 |
2022-02-08 |
Macrogenics, Inc. |
ADAM9-binding molecules, and methods of use thereof
|
CN110382537B
(zh)
|
2017-02-02 |
2023-07-25 |
默克专利有限公司 |
抗体结构域的优选配对
|
EP4389226A2
(en)
|
2017-02-24 |
2024-06-26 |
MacroGenics, Inc. |
Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
|
SG11201909218RA
(en)
|
2017-04-03 |
2019-11-28 |
Hoffmann La Roche |
Antibodies binding to steap-1
|
CN110392698B
(zh)
|
2017-04-05 |
2022-01-25 |
豪夫迈·罗氏有限公司 |
抗lag3抗体
|
US11285207B2
(en)
|
2017-04-05 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Bispecific antibodies specifically binding to PD1 and LAG3
|
KR20200092301A
(ko)
*
|
2017-06-25 |
2020-08-03 |
시스트이뮨, 인코포레이티드 |
다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도
|
WO2019005640A2
(en)
*
|
2017-06-25 |
2019-01-03 |
Systimmune, Inc. |
MULTISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING SAME
|
AU2018292438A1
(en)
|
2017-06-30 |
2019-12-12 |
Zymeworks Bc Inc. |
Stabilized chimeric fabs
|
EP3645122A1
(en)
|
2017-06-30 |
2020-05-06 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
|
JP6951545B2
(ja)
*
|
2017-07-21 |
2021-10-20 |
トリアンニ インコーポレイテッドTrianni,Inc. |
単鎖vh及び重鎖抗体
|
US11161911B2
(en)
|
2017-10-23 |
2021-11-02 |
Go Therapeutics, Inc. |
Anti-glyco-MUC1 antibodies and their uses
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
JP2021502100A
(ja)
|
2017-11-08 |
2021-01-28 |
ゼンコア インコーポレイテッド |
新規抗pd−1配列を用いた二重特異性および単一特異性抗体
|
US20200300852A1
(en)
|
2017-11-29 |
2020-09-24 |
Hoffmann-La Roche Inc. |
Target interference suppressed anti-drug antibody assay
|
KR20200098590A
(ko)
|
2017-12-12 |
2020-08-20 |
마크로제닉스, 인크. |
이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도
|
AU2018390418B2
(en)
|
2017-12-19 |
2023-12-21 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
BR112020011469A2
(pt)
|
2017-12-21 |
2020-11-24 |
F. Hoffmann-La Roche Ag |
anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, uso do anticorpo, método de tratamento de uma doença e invenção
|
WO2019122054A1
(en)
|
2017-12-22 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
|
JP2021508471A
(ja)
|
2017-12-29 |
2021-03-11 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
抗vegf抗体のvegf受容体遮断選択性を改善する方法
|
EP3746480A1
(en)
|
2018-01-31 |
2020-12-09 |
F. Hoffmann-La Roche AG |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
CN111630063A
(zh)
|
2018-01-31 |
2020-09-04 |
豪夫迈·罗氏有限公司 |
稳定化的免疫球蛋白结构域
|
US11866498B2
(en)
|
2018-02-08 |
2024-01-09 |
Genentech, Inc. |
Bispecific antigen-binding molecules and methods of use
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
BR112020016485A2
(pt)
|
2018-02-15 |
2020-12-15 |
Macrogenics, Inc. |
Molécula de ligação, composição farmacêutica e método para o tratamento de uma doença
|
KR20200135510A
(ko)
|
2018-03-29 |
2020-12-02 |
제넨테크, 인크. |
포유류 세포들에서 젖분비자극 활성의 조절
|
EP3773911A2
(en)
|
2018-04-04 |
2021-02-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
EP3781598A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
AU2019256539A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
SG11202011633SA
(en)
|
2018-05-24 |
2020-12-30 |
Janssen Biotech Inc |
Psma binding agents and uses thereof
|
TW202016151A
(zh)
|
2018-06-09 |
2020-05-01 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
CN112135626B
(zh)
|
2018-07-25 |
2023-05-23 |
信达生物制药(苏州)有限公司 |
抗tigit抗体及其用途
|
EP3608674A1
(en)
|
2018-08-09 |
2020-02-12 |
Regeneron Pharmaceuticals, Inc. |
Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
|
AU2019355971A1
(en)
|
2018-10-03 |
2021-05-06 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
CN109633053B
(zh)
*
|
2018-12-19 |
2021-04-30 |
杭州奕安济世生物药业有限公司 |
细胞培养物蛋白质表达量和蛋白质聚集体量的检测方法
|
MY194642A
(en)
|
2018-12-21 |
2022-12-09 |
Hoffmann La Roche |
Antibodies binding to cd3
|
WO2020136566A1
(en)
|
2018-12-24 |
2020-07-02 |
Sanofi |
Multispecific binding proteins with mutant fab domains
|
WO2020136060A1
(en)
|
2018-12-28 |
2020-07-02 |
F. Hoffmann-La Roche Ag |
A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
|
CN113227789A
(zh)
|
2018-12-30 |
2021-08-06 |
豪夫迈·罗氏有限公司 |
基于pH梯度SPR的结合测定
|
CA3132185A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
EP3947440A1
(en)
|
2019-03-29 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Method for generating avid-binding multispecific antibodies
|
WO2020200941A1
(en)
|
2019-03-29 |
2020-10-08 |
F. Hoffmann-La Roche Ag |
Spr-based binding assay for the functional analysis of multivalent molecules
|
CN113747944A
(zh)
|
2019-04-19 |
2021-12-03 |
詹森生物科技公司 |
用抗psma/cd3抗体治疗***癌的方法
|
CN113811770B
(zh)
|
2019-05-13 |
2024-06-28 |
豪夫迈·罗氏有限公司 |
抑制干扰的药代动力学免疫测定
|
CN113993887A
(zh)
|
2019-06-19 |
2022-01-28 |
豪夫迈·罗氏有限公司 |
通过以限定的组织形式靶向整合多个表达盒来产生多价双特异性抗体表达细胞的方法
|
WO2020254352A1
(en)
|
2019-06-19 |
2020-12-24 |
F. Hoffmann-La Roche Ag |
Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
CA3140192A1
(en)
|
2019-06-19 |
2020-12-24 |
Johannes Auer |
Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
EP3986928A1
(en)
|
2019-06-19 |
2022-04-27 |
F. Hoffmann-La Roche AG |
Method for the generation of a protein expressing cell by targeted integration using cre mrna
|
MX2021015538A
(es)
|
2019-06-19 |
2022-02-10 |
Hoffmann La Roche |
Metodo para la generacion de una celula que expresa un anticuerpo biespecifico bivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida.
|
EP3990646A1
(en)
|
2019-06-26 |
2022-05-04 |
F. Hoffmann-La Roche AG |
Mammalian cell lines with sirt-1 gene knockout
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
PE20220394A1
(es)
|
2019-07-31 |
2022-03-18 |
Hoffmann La Roche |
Anticuerpos que se fijan a gprc5d
|
JP2022543551A
(ja)
|
2019-07-31 |
2022-10-13 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Gprc5dに結合する抗体
|
JP2022543669A
(ja)
|
2019-08-08 |
2022-10-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
新規抗原結合分子フォーマット
|
AU2020349509A1
(en)
|
2019-09-18 |
2022-03-31 |
Genentech, Inc. |
Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
|
JP2022553640A
(ja)
|
2019-10-10 |
2022-12-26 |
コディアック サイエンシーズ インコーポレイテッド |
眼障害を処置する方法
|
CN114641270A
(zh)
|
2019-11-15 |
2022-06-17 |
豪夫迈·罗氏有限公司 |
防止水性蛋白质溶液中可见颗粒的形成
|
PE20221661A1
(es)
|
2019-12-18 |
2022-10-26 |
Hoffmann La Roche |
Anticuerpos anti-ccl2 biespecificos
|
BR112022011854A2
(pt)
|
2019-12-18 |
2022-09-06 |
Hoffmann La Roche |
Anticorpos, polinucleotídeo isolado, célula hospedeira, métodos para produzir um anticorpo e para tratar uma doença, composição farmacêutica, usos do anticorpo e invenção
|
BR112022012439A2
(pt)
|
2019-12-23 |
2022-09-06 |
Genentech Inc |
Anticorpos isolados, ácido nucleico isolado, vetor isolado, célula hospedeira isolada e métodos para produzir um anticorpo que se liga à apol1, para detectar apolipoproteína l1 em uma amostra, para distinguir apolipoproteína l1 endógena, para distinguir as formas g0 e g1 de apolipoproteína l1 da forma apol1 g2 e para detectar especificamente células de podócitos
|
JP2023508596A
(ja)
|
2020-01-02 |
2023-03-02 |
エフ. ホフマン-ラ ロシュ アーゲー |
脳内の治療用抗体の量を決定するための方法
|
WO2021144422A1
(en)
|
2020-01-15 |
2021-07-22 |
F. Hoffmann-La Roche Ag |
Methods to decrease impurities from recombinant protein manufacturing processes
|
CN115315512A
(zh)
|
2020-03-26 |
2022-11-08 |
基因泰克公司 |
具有降低的宿主细胞蛋白质的经修饰的哺乳动物细胞
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
JP2023520249A
(ja)
|
2020-05-15 |
2023-05-16 |
エフ. ホフマン-ラ ロシュ アーゲー |
非経口タンパク質溶液中の可視粒子形成の防止方法
|
EP4153130A1
(en)
|
2020-05-19 |
2023-03-29 |
F. Hoffmann-La Roche AG |
The use of chelators for the prevention of visible particle formation in parenteral protein solutions
|
PE20240080A1
(es)
|
2020-06-08 |
2024-01-16 |
Hoffmann La Roche |
Anticuerpos anti-hbv y metodos de uso
|
WO2021254926A1
(en)
|
2020-06-16 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Method for determining the free antigen of an antibody in a sample
|
JP2023531625A
(ja)
|
2020-06-19 |
2023-07-25 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
CD3及びFolR1に結合する抗体
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
WO2021255142A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
AU2021291011A1
(en)
|
2020-06-19 |
2023-01-05 |
F. Hoffmann-La Roche Ag |
Antibodies binding to CD3 and CD19
|
US20220041672A1
(en)
|
2020-06-24 |
2022-02-10 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
EP4175650A1
(en)
|
2020-07-06 |
2023-05-10 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
CN116133689A
(zh)
|
2020-07-07 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
作为治疗性蛋白质制剂的稳定剂的替代表面活性剂
|
PE20231300A1
(es)
|
2020-07-17 |
2023-08-24 |
Genentech Inc |
Anticuerpos anti-notch2 y metodos de uso
|
KR102607909B1
(ko)
|
2020-08-19 |
2023-12-01 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
TW202227625A
(zh)
|
2020-08-28 |
2022-07-16 |
美商建南德克公司 |
宿主細胞蛋白質之CRISPR/Cas9多重剔除
|
CA3191328A1
(en)
|
2020-09-21 |
2022-03-24 |
Genentech, Inc. |
Purification of multispecific antibodies
|
US20220154207A1
(en)
|
2020-09-24 |
2022-05-19 |
Hoffmann-La Roche Inc. |
Mammalian cell lines with gene knockout
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
CA3202233A1
(en)
|
2020-11-18 |
2022-05-27 |
Kiromic BioPharma, Inc. |
Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
|
KR20220082775A
(ko)
|
2020-12-10 |
2022-06-17 |
주식회사 유틸렉스 |
항-pd-1 항체 및 이의 용도
|
EP4263609A1
(en)
|
2020-12-17 |
2023-10-25 |
F. Hoffmann-La Roche AG |
Anti-hla-g antibodies and use thereof
|
JP2024501662A
(ja)
|
2020-12-22 |
2024-01-15 |
エフ. ホフマン-ラ ロシュ アーゲー |
Xbp1を標的とするオリゴヌクレオチド
|
CA3203257A1
(en)
|
2020-12-23 |
2022-06-30 |
Li Li |
Anti-b7-h3 antibody and uses thereof
|
KR20220095163A
(ko)
*
|
2020-12-29 |
2022-07-06 |
삼성바이오로직스 주식회사 |
이중 또는 다중 특이적 항체
|
CN114716548A
(zh)
|
2021-01-05 |
2022-07-08 |
(株)爱恩德生物 |
抗-fgfr3抗体及其用途
|
KR20230137393A
(ko)
|
2021-01-28 |
2023-10-04 |
얀센 바이오테크 인코포레이티드 |
Psma 결합 단백질 및 이의 용도
|
EP4288458A1
(en)
|
2021-02-03 |
2023-12-13 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
JP2024512240A
(ja)
|
2021-02-18 |
2024-03-19 |
エフ. ホフマン-ラ ロシュ アーゲー |
複雑な多段階の抗体相互作用を解明するための方法
|
TWI830151B
(zh)
*
|
2021-02-19 |
2024-01-21 |
大陸商信達生物製藥(蘇州)有限公司 |
抗GPRC5DxBCMAxCD3三特異性抗體及其用途
|
IL305736A
(en)
|
2021-03-09 |
2023-11-01 |
Xencor Inc |
Heterodimeric antibodies that bind CD3 and CLDN6
|
EP4305065A1
(en)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
WO2022192647A1
(en)
|
2021-03-12 |
2022-09-15 |
Genentech, Inc. |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
JP2024513474A
(ja)
|
2021-04-09 |
2024-03-25 |
エフ. ホフマン-ラ ロシュ アーゲー |
異種ポリペプチドを発現する細胞クローンを選択するための方法
|
CA3215965A1
(en)
|
2021-04-19 |
2022-10-27 |
Amy Shen |
Modified mammalian cells
|
JP2024521107A
(ja)
|
2021-05-21 |
2024-05-28 |
ジェネンテック, インコーポレイテッド |
目的の組換え産物を産生するための修飾細胞
|
CN113278071B
(zh)
|
2021-05-27 |
2021-12-21 |
江苏荃信生物医药股份有限公司 |
抗人干扰素α受体1单克隆抗体及其应用
|
CN117957256A
(zh)
*
|
2021-06-17 |
2024-04-30 |
勃林格殷格翰国际有限公司 |
新颖三特异性结合分子
|
CN117500829A
(zh)
|
2021-06-18 |
2024-02-02 |
豪夫迈·罗氏有限公司 |
双特异性抗ccl2抗体
|
KR20240032930A
(ko)
|
2021-07-13 |
2024-03-12 |
제넨테크, 인크. |
사이토카인 방출 증후군을 예측하기 위한 다변량 모델
|
WO2023284806A1
(zh)
*
|
2021-07-14 |
2023-01-19 |
江苏恒瑞医药股份有限公司 |
特异性结合cd38、bcma和cd3的抗原结合分子及其医药用途
|
EP4373859A1
(en)
|
2021-07-22 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Heterodimeric fc domain antibodies
|
WO2023012147A1
(en)
|
2021-08-03 |
2023-02-09 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use
|
CN113603775B
(zh)
|
2021-09-03 |
2022-05-20 |
江苏荃信生物医药股份有限公司 |
抗人白介素-33单克隆抗体及其应用
|
CN113683694B
(zh)
|
2021-09-03 |
2022-05-13 |
江苏荃信生物医药股份有限公司 |
一种抗人tslp单克隆抗体及其应用
|
CN118284809A
(zh)
|
2021-11-25 |
2024-07-02 |
豪夫迈·罗氏有限公司 |
少量抗体副产物的定量
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
WO2023117325A1
(en)
|
2021-12-21 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Method for the determination of hydrolytic activity
|
WO2023129974A1
(en)
|
2021-12-29 |
2023-07-06 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
US20230322958A1
(en)
|
2022-01-19 |
2023-10-12 |
Genentech, Inc. |
Anti-Notch2 Antibodies and Conjugates and Methods of Use
|
WO2023175171A1
(en)
|
2022-03-18 |
2023-09-21 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Bk polyomavirus antibodies and uses thereof
|
WO2023202967A1
(en)
|
2022-04-19 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
WO2023232961A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024079015A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and imids
|
WO2024079010A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and cd38 antibodies
|
WO2024079009A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and proteasome inhibitors
|
WO2024079069A1
(en)
|
2022-10-12 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Method for classifying cells
|
WO2024110426A1
(en)
|
2022-11-23 |
2024-05-30 |
F. Hoffmann-La Roche Ag |
Method for increasing recombinant protein expression
|
WO2024129594A1
(en)
|
2022-12-12 |
2024-06-20 |
Genentech, Inc. |
Optimizing polypeptide sialic acid content
|
CN117805397A
(zh)
*
|
2024-02-29 |
2024-04-02 |
军科正源(北京)药物研究有限责任公司 |
检测游离vegf的方法
|